Rights issue takes Expres2ion breast cancer vaccine to phase I

Having validated its vaccine platform in Covid-19, Expres2ion Biotech now turns to the treatment of breast cancer.

A SEK 60 million rights issue of units will fund a phase I study with the breast cancer vaccine candidate ES2B-C001, building on promising preclinical results.